Clinical Trial Update: Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating intramuscular olanzapine depot in patients with schizophrenia or schizoaffective disorder; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• olanzapine depot (olanzapine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Schizophrenic Disorders, Schizoaffective Disorder | Phase 3 | Status: COMPLETED | Results posted: 2012-01-11